LCMV gp33-41,羧基延伸的11-aa-长肽,受 MHC I 类 H-2Db 分子限制的淋巴细胞脉络丛脑膜炎病毒序列,可呈递给细胞毒性 T 淋巴细胞。
LCMV gp33-41 Chemical Structure
CAS No. : 151705-84-9
规格
价格
是否有货
数量
1 mg
¥900
In-stock
5 mg
¥1900
In-stock
10 mg
¥2900
In-stock
50 mg
;
询价
;
100 mg
;
询价
;
* Please select Quantity before adding items.
LCMV gp33-41 相关产品
•相关化合物库:
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Peptide Library
生物活性
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].
分子量
1044.22
Formula
FTKNVY
CAS 号
151705-84-9
Sequence
Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Met
Sequence Shortening
KAVYNFATM
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.
LCMV gp33-41 (TFA),羧基延伸的 11-aa-长肽,受 MHC I 类 H-2Db 分子限制的淋巴细胞脉络丛脑膜炎病毒序列,可呈递给细胞毒性 T 淋巴细胞。
LCMV gp33-41 TFA Chemical Structure
规格
价格
是否有货
数量
10;mM;*;1 mL in DMSO
¥3690
In-stock
1 mg
¥900
In-stock
5 mg
¥1900
In-stock
10 mg
¥2900
In-stock
50 mg
;
询价
;
100 mg
;
询价
;
* Please select Quantity before adding items.
LCMV gp33-41 TFA 相关产品
bull;相关化合物库:
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Peptide Library
生物活性
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].
分子量
1158.24
Formula
C50H74N11F3015S
Sequence
Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Met
Sequence Shortening
KAVYNFATM
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.
LCMV GP (61-80) 是衍生自淋巴细胞性脉络丛脑膜炎病毒 (LCMV) 糖蛋白 (GP) 的多肽片段,对应于 61-80 氨基酸序列。LCMV GP (61-80) 是一种特异性抗原决定簇,可以诱导 CD4+ T 细胞反应。
LCMV GP (61-80) Chemical Structure
CAS No. : 232598-19-5
规格
是否有货
100 mg
;
询价
;
250 mg
;
询价
;
500 mg
;
询价
;
* Please select Quantity before adding items.
生物活性
LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4+ T-cell response[1][2][3].
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;
H2O
Peptide Solubility and Storage Guidelines:
1.;;Calculate the length of the peptide.
2.;;Calculate the overall charge of the entire peptide according to the following table:
;
Contents
Assign value
Acidic amino acid
Asp (D), Glu (E), and the C-terminal -COOH.
-1
Basic amino acid
Arg (R), Lys (K), His (H), and the N-terminal -NH2
+1
Neutral amino acid
Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)
0
3.;;Recommended solution:
Overall charge of peptide
Details
Negative (lt;0)
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH4OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0)
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)
1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
[1]. Rodriguez F, et, al. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol. 2001 Nov; 75(21): 10421-30.
[2]. Andargachew R, et, al. CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection. J Immunol. 2018 Jul 1; 201(1):19-30.
[3]. Homann D, et, al. Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. Virology. 2007 Jun 20; 363(1): 113-23.